美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

三倍做多標普生物-Direxion

256.83

+6.432.57%

成交量：5.91萬

成交額：1,516.08萬

市值：5.07億

市盈率：- -

高：259.40

開：255.78

低：251.70

收：250.40

52周最高：341.93

52周最低：76.29

股本：197.45萬

流通股本：197.45萬

量比：3.39

換手率：2.99%

股息：1.00

股息率：0.39%

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

大家人壽9.8億元投資接力基金後者投向硬科技、醫療健康等領域

泰達生物(08189)與星辰通用簽署戰略合作框架協議共同推動醫療健康具身智能技術體系、產品體系和解決方案的形成與產業化落地

英國藥品和醫療保健產品監管局已受理Biosplice公司關於洛雷西文特治療膝骨關節炎的申請，並正式啓動評估程序。

醫療保健板塊市場快訊匯總

醫療保健板塊動態：市場快訊匯總

醫療保健板塊市場快訊匯總

2070元/月，佛山這筆錢上調

醫療健康板塊動態：市場快訊匯總

人保健康保險大連分公司被罰27萬，涉聘任不合格人員等

阿斯利康(AZN.US)乳腺癌新藥獲FDA加速批准，華爾街預計2032年銷售額有望衝刺23億美元

阿斯利康(AZN.US)乳腺癌新藥獲FDA加速批准，華爾街預計2032年銷售額有望衝刺23億美元

美國食品藥品監督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用於治療伴有ESR1突變的晚期乳腺癌。

醫療健康板塊動態：市場快訊匯總

丹陽家長注意！2027年度學生醫保繳費啓動

一項針對僱主的調查預計，美國醫療保健成本將出現20多年來最大漲幅：2027年僱主提供的醫療保險成本預計將較今年上升8.2

醫療板塊市場快訊：和黃醫藥與GSK達成許可協議，AstraZeneca新藥前景獲看好

醫療保健板塊市場快訊：比特幣漲勢帶動加密市場樂觀情緒，阿斯利康新藥潛力引關注

醫療健康板塊市場綜述：行業動態與個股追蹤

美國衞生與公眾服務部醫療保險和醫療補助服務中心：特朗普政府宣佈撥款1.2億美元，用於擴大印第安納州母嬰健康服務，提高初級

中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.thetigerbrokers.com/hant/stock/LABU/news?page=3"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"LABU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","market":"US","secType":"STK","nameCN":"三倍做多標普生物-Direxion","latestPrice":256.8271,"timestamp":1789566935046,"preClose":250.4,"halted":0,"volume":59095,"delay":0,"changeRate":0.025667332268370476,"floatShares":1974486,"shares":1974486,"eps":0,"marketStatus":"交易中","change":6.4271,"latestTime":"09-16 09:55:35 EDT","open":255.78,"high":259.395,"low":251.7,"amount":15160844.706100002,"amplitude":0.030731,"askPrice":257.92,"askSize":10,"bidPrice":256.9,"bidSize":10,"shortable":3,"etf":3,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1789588800000},"marketStatusCode":2,"adr":0,"adrRate":0,"exchange":"ARCA","adjPreClose":250.4,"sharesOutstanding":3074486,"nav":268.659,"aum":530464172.89,"dividendRate":0.0039,"bidAskSpread":0.003539,"preHourTrading":{"tag":"盘前","latestPrice":254.8128,"preClose":250.4,"latestTime":"09:28 EDT","volume":4289,"amount":1082884.5326099999,"timestamp":1789565312693,"change":4.4128,"changeRate":0.017623,"amplitude":0.012511},"postHourTrading":{"tag":"盘后","latestPrice":251.98,"preClose":250.4,"latestTime":"19:59 EDT","volume":8108,"amount":2036460.6035,"timestamp":1789516773600,"change":1.58,"changeRate":0.00631,"amplitude":0.00631},"volumeRatio":3.392085,"impliedVol":0.9286,"impliedVolPercentile":0.5697},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"LABU\",,,,,undefined,":{"symbol":"LABU","floatShares":1974486,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":3.392085,"shares":1974486,"dividePrice":1.0016,"high":259.395,"amplitude":0.030731,"preClose":250.4,"low":251.7,"week52Low":76.29,"pbRate":"--","week52High":341.93,"institutionHeld":0,"latestPrice":256.8271,"eps":0,"divideRate":0.0039,"volume":59095,"delay":0,"ttmEps":0,"open":255.78,"prevYearClose":159.39,"prevWeekClose":261.3,"prevMonthClose":296.31,"prevQuarterClose":292.1,"fiveDayClose":279.02,"twentyDayClose":289.98,"sixtyDayClose":230.01},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/LABU\",params:#limit:5,,,undefined,":[{"date":"2025-09-23","symbol":"LABU","amount":0.10273,"announcedDate":"2025-09-22","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-09-23","defaultRemindTime":1758634200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-09-30","payableDate":"2025-09-23","currency":"USD","dateTimestamp":1758600000000,"payDate":"2025-09-30"},{"date":"2025-06-24","symbol":"LABU","amount":0.21897,"announcedDate":"2025-06-23","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-06-24","defaultRemindTime":1750771800000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-07-01","payableDate":"2025-06-24","currency":"USD","dateTimestamp":1750737600000,"payDate":"2025-07-01"},{"date":"2025-03-25","symbol":"LABU","amount":0.10714,"announcedDate":"2025-03-24","type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2025-03-25","defaultRemindTime":1742909400000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2025-04-01","payableDate":"2025-03-25","currency":"USD","dateTimestamp":1742875200000,"payDate":"2025-04-01"},{"date":"2024-06-25","symbol":"LABU","amount":0.15021,"announcedDate":null,"type":"dividend","lastAmount":null,"market":"US","newRecordDate":"2024-06-25","defaultRemindTime":1719322200000,"name":"三倍做多标普生物-Direxion","lastCurrency":null,"lastExecuteDate":null,"recordDate":"2024-07-02","payableDate":"2024-06-25","currency":"USD","dateTimestamp":1719288000000,"payDate":"2024-07-02"},{"date":"2024-03-19","symbol":"LABU","amount":0.16064,"announcedDate":"2024-03-18","type":"dividend","market":"US","newRecordDate":"2024-03-20","defaultRemindTime":1710855000000,"name":"三倍做多标普生物-Direxion","recordDate":"2024-03-26","payableDate":"2024-03-20","currency":"USD","dateTimestamp":1710820800000,"payDate":"2024-03-26"}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"LABU\",market:\"US\",,,undefined,":[{"executeDate":"2018-06-19","recordDate":"2018-06-20","paymentDate":"2018-06-26","value":0.01932,"currency":"USD"},{"executeDate":"2018-09-25","recordDate":"2018-09-26","paymentDate":"2018-10-02","value":0.0954,"currency":"USD"},{"executeDate":"2018-12-27","recordDate":"2018-12-28","paymentDate":"2019-01-04","value":0.09621,"currency":"USD"},{"executeDate":"2019-03-19","recordDate":"2019-03-20","paymentDate":"2019-03-26","value":0.10973,"currency":"USD"},{"executeDate":"2019-06-25","recordDate":"2019-06-26","paymentDate":"2019-07-02","value":0.03745,"currency":"USD"}],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"LABU\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"LABU\",pageSize:20,pageCount:3,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2665273123","title":"大家人壽9.8億元投資接力基金 後者投向硬科技、醫療健康等領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2665273123","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665273123?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 19:25","pubTimestamp":1788866725,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","XBI","IXJ","VHT","BK4585","BK4581","BK4550","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665324454","title":"泰達生物(08189)與星辰通用簽署戰略合作框架協議 共同推動醫療健康具身智能技術體系、產品體系和解決方案的形成與產業化落地","url":"https://stock-news.laohu8.com/highlight/detail?id=2665324454","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665324454?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:40","pubTimestamp":1788864000,"startTime":"0","endTime":"0","summary":"智通财经APP讯，泰达生物 公布，公司与湖南星辰通用机器人有限公司已签署战略合作框架协议。双方将本着平等自愿、优势互补、场景牵引、联合创新、资源共享、长期合作的原则，围绕医疗健康大模型与具身智能技术的深度融合，共同推动医疗健康具身智能技术体系、产品体系和解决方案的形成与产业化落地。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493464.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","IXJ","XLV","159760","BK4585","BK4550","XBI","LABU","BK4588","WDRN","08189","BK1113","VHT"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665654324","title":"英國藥品和醫療保健產品監管局已受理Biosplice公司關於洛雷西文特治療膝骨關節炎的申請，並正式啓動評估程序。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665654324","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665654324?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 18:33","pubTimestamp":1788863626,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["NOBL","BK4581","BK4550","BK4585","LABU","CGVV","BK4588","VHT","XBI","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1169238098","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1169238098","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1169238098?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 16:25","pubTimestamp":1788855909,"startTime":"0","endTime":"0","summary":"不过，分析师注意到，公司对2030年后实现中个位数百分比增长的雄心未作任何表态。杰富瑞认为，即便近期一款多发性硬化症口服新药取得了成功，但若缺少del-desiran和del-brax这两款自Avidity Biosciences收购而来的药物，要确立市场对公司2030年代增长前景的信心仍面临重重挑战。该公司股价下挫10%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","XBI","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1166930636","title":"醫療保健板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1166930636","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1166930636?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 04:52","pubTimestamp":1788814379,"startTime":"0","endTime":"0","summary":"1035 ET - 杰富瑞分析师指出，阿斯利康凭借其新药Ectamah正在开辟乳腺癌治疗的全新范式，该药刚刚获得美国食品药品监督管理局的上市许可。分析师们认为，这无疑是近年来乳腺癌领域最具分量的批准之一。尽管Ectamah的获批具有重大临床意义，但杰富瑞也提醒，目前其适用人群仅为全体乳腺癌患者中的一部分，这在短期内限制了其商业价值。该公司股价小幅上扬0.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","BK4581","BK4585","XLV","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1124637396","title":"醫療保健板塊市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1124637396","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1124637396?lang=zh_tw&edition=fundamental","pubTime":"2026-09-08 00:22","pubTimestamp":1788798177,"startTime":"0","endTime":"0","summary":"1035 GMT——杰富瑞分析师指出，阿斯利康凭借其新药Ectamah，正在开启乳腺癌治疗的全新范式，该药物刚刚获得美国食品药品监督管理局的批准。分析师评价，这堪称近年来乳腺癌领域最具分量的审批之一。不过杰富瑞也提醒，尽管Ectamah获批在临床上意义重大，但目前其适用人群仅为全体乳腺癌患者中的特定亚群，这在一定程度上限制了其商业价值。该公司股价上涨0.5%。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4585","XLV","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665315217","title":"2070元/月，佛山這筆錢上調","url":"https://stock-news.laohu8.com/highlight/detail?id=2665315217","media":"珠江时报","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665315217?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 18:00","pubTimestamp":1788775200,"startTime":"0","endTime":"0","summary":"随着佛山市最低工资标准9月1日失业金自待遇所属期2026年9月起上调至2070元/月。（二）享受的待遇标准1、失业保险金：按我市企业职工最低工资标准的90%按月发放，待遇所属期2026年9月起是2070元/月。大龄领金人员达到法定退休年龄时，或出现停止领取失业保险金情形的，停止享受由失业保险基金继续承担企业职工基本养老保险费。2025年2月1日及之后申请失业保险金的失业人员，按修改后的省条例执行，不再发放求职补贴。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-07/doc-iniqyzxu6360828.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["BK4588","XBI","BK4581","LABU","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1175448508","title":"醫療健康板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1175448508","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1175448508?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 16:23","pubTimestamp":1788769386,"startTime":"0","endTime":"0","summary":"0727 GMT——CGS国际分析师Kasem Prunratanamala在研报中指出，Klinique医疗诊所上调了2026年营收指引，但这一利好消息似乎已被市场提前消化。这家医疗美容诊所运营商将2026年营收目标从41.5亿泰铢上调至45亿泰铢，理由是7月份现金销售增长强劲。尽管公司运营势头稳健，同店销售增长韧性十足，但近期股价的强势表现已充分反映了大部分正面消息。该券商维持该股\"持有\"评级及28.00泰铢的目标价。目前股价报29.00泰铢，上涨1.75%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","LABU","BK4581","BK4588","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665954553","title":"人保健康保險大連分公司被罰27萬，涉聘任不合格人員等","url":"https://stock-news.laohu8.com/highlight/detail?id=2665954553","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665954553?lang=zh_tw&edition=fundamental","pubTime":"2026-09-07 10:47","pubTimestamp":1788749245,"startTime":"0","endTime":"0","summary":"蓝鲸新闻9月7日讯，近日，国家金融监督管理总局大连监管局发布行政处罚决定书，剑指中国人民健康保险股份有限公司大连分公司及相关责任人。罚单显示，中国人民健康保险股份有限公司大连分公司的主要违法违规行为是：聘任不具有任职资格的人员；编制、提供虚假的报告报表文件资料。针对上述违法行为，国家金融监督管理总局大连监管局对中国人民健康保险股份有限公司大连分公司罚款27万元；对傅信弘警告，罚款7万元；对周笑俊警告，罚款7万元；对刘志东警告，罚款1万元；对李翔警告，罚款4万元。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1788746879733984657","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["LABU","XLV","BK4585","BK4581","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665500873","title":"阿斯利康(AZN.US)乳腺癌新藥獲FDA加速批准，華爾街預計2032年銷售額有望衝刺23億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665500873","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665500873?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 13:50","pubTimestamp":1788587400,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，阿斯利康的乳腺癌口服药已获得美国食品药品监督管理局的批准。阿斯利康曾表示，商品名为 Etcamah 的 camizestrant 最终有望带来超过 50 亿美元的年销售额。然而华尔街并未如此乐观：调查的分析师目前预计，该药在 2032 年的销售额近 23 亿美元。但在周五的批准声明中，该机构表示，这种药物将为乳腺癌女性患者提供一种额外的疾病治疗途径。该药适用于在接受内分泌疗法期间产生特定基因突变的乳腺癌患者。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1492433.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["LABU","BK4585","FAZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665350082","title":"阿斯利康(AZN.US)乳腺癌新藥獲FDA加速批准，華爾街預計2032年銷售額有望衝刺23億美元","url":"https://stock-news.laohu8.com/highlight/detail?id=2665350082","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665350082?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 13:50","pubTimestamp":1788587400,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["LABU","BK4585","FAZ","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665935968","title":"美國食品藥品監督管理局（FDA）加速批准阿斯利康(AZN.O)的Etcamah，用於治療伴有ESR1突變的晚期乳腺癌。","url":"https://stock-news.laohu8.com/highlight/detail?id=2665935968","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2665935968?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 03:47","pubTimestamp":1788551256,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["LU2237443549.SGD","LU0708994859.HKD","BK4568","LU1267930573.SGD","BK4007","LU2237443622.USD","LU2417539215.USD","159151","BK4585","AZNH","LU1829250122.USD","LU0889565916.HKD","LU0058720904.USD","LU2468319806.SGD","AZN","LU2236285917.USD","LU2462157665.USD","LU0029864427.USD","LU2237443895.HKD","LU2237443382.USD","LU0128525929.USD","BK4588","LU0432979614.USD","LU2237443465.HKD","LU0289739699.SGD","IE00B3T34201.USD","LABU","LU0310800379.SGD","LU0320765992.SGD","LU2089984988.USD","LU2237443978.SGD","LU2456880835.USD","LU0109394709.USD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1136673456","title":"醫療健康板塊動態：市場快訊匯總","url":"https://stock-news.laohu8.com/highlight/detail?id=1136673456","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1136673456?lang=zh_tw&edition=fundamental","pubTime":"2026-09-05 00:24","pubTimestamp":1788539073,"startTime":"0","endTime":"0","summary":"最新一期聚焦医疗健康领域的市场快讯已经发布，仅在道琼斯通讯社平台独家呈现，更新时段分别为美东时间凌晨4:20、中午12:20及下午4:50。分析师们认为，此项交易、上半年销售势头以及中国监管机构另行批准的进展，或将显著提升市场对和黄医药业绩指引的可见度。该公司预计2026年肿瘤学与免疫学领域收入将在3.3亿至4.5亿美元之间。目前该公司股价报22.60港元，涨幅为3.3%。以太坊上涨4.7%至2,506美元，瑞波币攀升7.4%至1.45美元，Solana则上涨4.8%至104.45美元。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XBI","BK4581","BK4588","LABU","BK4585","XLV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664334816","title":"丹陽家長注意！2027年度學生醫保繳費啓動","url":"https://stock-news.laohu8.com/highlight/detail?id=2664334816","media":"丹阳发布","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664334816?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 20:05","pubTimestamp":1788523500,"startTime":"0","endTime":"0","summary":"为充分保障在校学生的医疗保险待遇，丹阳市2027年度学生参加城乡居民医疗保险的参保登记工作由学校统一为学生办理，个人缴费标准为450元，长期护理保险根据国家规定暂不单独筹资。被认定为资助参保救助对象的学生，可以选择参加认定地基本医疗保险，丹阳市救助学生个人缴费部分由社会医疗救助基金承担，个人无需缴费。同一年度第二次住院，起付标准按相应医疗机构级别标准降低50%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/wm/2026-09-04/doc-iniqskun4096571.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["XLV","BK4588","XBI","BK4581","BK4585","LABU"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664380422","title":"一項針對僱主的調查預計，美國醫療保健成本將出現20多年來最大漲幅：2027年僱主提供的醫療保險成本預計將較今年上升8.2","url":"https://stock-news.laohu8.com/highlight/detail?id=2664380422","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664380422?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:43","pubTimestamp":1788511437,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","BK4581","BK4585","XLV","MHIG","LABU","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1161674237","title":"醫療板塊市場快訊：和黃醫藥與GSK達成許可協議，AstraZeneca新藥前景獲看好","url":"https://stock-news.laohu8.com/highlight/detail?id=1161674237","media":"投资观察","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1161674237?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 16:22","pubTimestamp":1788510155,"startTime":"0","endTime":"0","summary":"花旗分析师在报告中指出，和黄医药与葛兰素史克达成的合作协议，实际上是对这家总部位于香港的生物制药公司某一特定候选药物平台的价值背书——尽管该药物尚未进入临床试验阶段。此番和黄医药与GSK签署的授权协议，在剔除净销售额特许权使用费后，潜在交易总额最高可达12.95亿美元，标的为一种癌症治疗药物。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4588","LABU","BK4581","XLV","XBI","BK4585"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1154879404","title":"醫療保健板塊市場快訊：比特幣漲勢帶動加密市場樂觀情緒，阿斯利康新藥潛力引關注","url":"https://stock-news.laohu8.com/highlight/detail?id=1154879404","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1154879404?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 04:58","pubTimestamp":1788469126,"startTime":"0","endTime":"0","summary":"最新一期的医疗保健板块市场快讯已发布，涵盖多家重要企业的动态与分析师观点。比特币自8月以来的上涨走势，为加密货币市场注入了乐观情绪。\"目前，比特币已突破8万美元大关，最新报81,054美元，涨幅达4.7%。\"阿斯利康股价上涨1.5%。在英国市场，一项重大新合同的整合延迟以及劳动力成本正在拖累业绩表现。\"Jefferies维持对Sonic的持有评级，目标价定为每股21.00澳元，该股周三收于18.73澳元。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["XLV","LABU","XBI","BK4588","BK4585","BK4581"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1188599563","title":"醫療健康板塊市場綜述：行業動態與個股追蹤","url":"https://stock-news.laohu8.com/highlight/detail?id=1188599563","media":"投资观察","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1188599563?lang=zh_tw&edition=fundamental","pubTime":"2026-09-04 00:22","pubTimestamp":1788452559,"startTime":"0","endTime":"0","summary":"0810 GMT——Berenberg分析师在研究报告中指出，阿斯利康治疗慢性阻塞性肺病的新药若能在所有患者群体中展现出有效性，有望成为该领域的市场领军者。这家英国药企今年早些时候公布的初期试验结果显示，托佐利单抗在既往吸烟者的主要人群及整体人群中均带来了获益，且在不同肺功能阶段皆展现疗效。Berenberg表示：“我们认为减少30%的急性加重将是一个极为积极的结果，且超出预期。”该公司股价上涨1.5%。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LABU","XLV","BK4585","BK4581","BK4588","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664877326","title":"美國衞生與公眾服務部醫療保險和醫療補助服務中心：特朗普政府宣佈撥款1.2億美元，用於擴大印第安納州母嬰健康服務，提高初級","url":"https://stock-news.laohu8.com/highlight/detail?id=2664877326","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664877326?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 21:22","pubTimestamp":1788441723,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["XBI","SG9999014021.USD","LU0320765489.SGD","LU0070302665.USD","BK4566","HUM","LU1983260115.SGD","RSPH","LABU","BK4533","LU0348723411.USD","LU0238689110.USD","LU1093756325.SGD","LU0208291251.USD","FXH","LU0266013472.USD","BK4154","LU0211331839.USD","LU0256863811.USD","SG9999014005.SGD","LU1093756168.USD","BK4585","LU0417517546.SGD","BK4588","SG9999014013.SGD","LU0170899867.USD","XLV","BK4581","LU0390134368.USD","IHF"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664872828","title":"中國生物製藥(01177.HK)：TQB6426「GPC3 ADC」臨床試驗申請獲FDA批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2664872828","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664872828?lang=zh_tw&edition=fundamental","pubTime":"2026-09-03 20:42","pubTimestamp":1788439353,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=usstock","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK4585","BK4588","IBBJ","IBBQ","PSYK","BMED","MDTX","LABU"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":10,"pageCount":3,"totalSize":200,"code":"91000000","status":"200"}]}}